Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans have been conditionally recommended in draft guidance.

A quick guide for care home managers More than half of older adults who live in care homes have tooth decay, compared to 40% of over 75s who do not live in care homes. Poor oral health can affect ...

Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.

Find out what guidance is being considered for development ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 ...

We're looking for health, social care and other professionals and practitioners to take an active role in producing a NICE guideline or quality standard.

Discussing medicines support Make sure medicines support is considered when assessing a person’s needs, consulting with healthcare colleagues if necessary. Talk to the person and (if they agree) their ...